Danish drugmaker Novo Nordisk’s promising data on its obesity drug Wegovy should spill over to also benefit Eli Lilly, a Wall Street bank says.
You are here: Home / Morgan Stanley sees Eli Lilly shares rallying on data showing heart benefit of Novo’s obesity drug